✨ Free AI Report
Skye Bioscience, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Skye Bioscience, Inc.
Company Research

Skye Bioscience, Inc.: Business Overview, Financials & Competitive Analysis

Skye Bioscience, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Phase 2 setbacks on monotherapy offset by strong combination data; obesity market opportunity significant but competitive landscape intensifying. The company's monotherapy arm missed primary endpoints in the Phase 2a CBeyond study with lower-than-expected drug exposure. However, 52-week combination data showed 22.3% total weight loss with nimacimab plus semaglutide with.

What is Skye Bioscience, Inc.'s industry? Skye Bioscience, Inc. (skyebioscience.com) operates in Biopharmaceuticals - Obesity and Metabolic Diseases. AskCyborg classifies Skye Bioscience, Inc. under Biopharmaceuticals - Obesity and Metabolic Diseases in its company registry.

Skye Bioscience is a clinical stage biopharmaceutical company focused on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product ca...

5/ 10Mixed

Cyborg Score thesis

Phase 2 setbacks on monotherapy offset by strong combination data; obesity market opportunity significant but competitive...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Obesity and Metabolic Diseases
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Skye Bioscience, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Skye Bioscience, Inc.

AskCyborg analysts argue the bull and bear cases for Skye Bioscience, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Skye Bioscience, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Skye Bioscience, Inc. Overview

Pro stress-test →

Skye Bioscience is a clinical stage biopharmaceutical company focused on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1).

Strategic Profile

Pro stress-test →

Nimacimab has the potential to address unmet needs in obesity left by GLP-1 and incretin pharmaceuticals. Skye's CB1 inhibitor is unique in being a monoclonal antibody that works outside the brain, avoiding neuropsychiatric side effects seen with earlier CB1 inhibitors. The company is conducting a Phase 2 clinical trial assessing nimacimab as a monotherapy and in combination with GLP-1 receptor agonist (Wegovy).

Competitive Landscape

Pro stress-test →

Skye competes in the rapidly expanding obesity therapeutics market dominated by GLP-1 receptor agonists (Novo Nordisk, Eli Lilly). Differentiation comes from CB1 mechanism and monoclonal antibody format avoiding CNS effects. Other emerging CB1 programs and dual/triple receptor agonists represent growing competition.

Industry Context

Skye Bioscience, Inc. operates in Biopharmaceuticals - Obesity and Metabolic Diseases.

Key facts

Founded: 2011 · Headquarters: San Diego, California · Market cap: $25M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Skye Bioscience, Inc..

  • Monotherapy arm of Phase 2a study missed primary endpoint with lower-than-expected drug exposure, suggesting need for higher dosing strategies
  • 52-week combination data impressive at 22.3% weight loss with semaglutide, showing durability and potential for further efficacy
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Reported positive 52-week Phase 2a extension interim results for nimacimab plus semaglutide combination
  • January 2026Announced global collaboration with Halozyme for higher-dose subcutaneous administration strategies
  • +2 moreTrack every material event for Skye Bioscience, Inc. as it happens. Explore monitoring →
Get alerted when Skye Bioscience, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Semaglutide/WegovyGLP-1 receptor agonist for obesity and weight management→Tirzepatide/ZepboundGLP-1/GIP receptor agonist for obesity and diabetes→Various CB1 Inhibitor ProgramsNext-generation obesity therapeutics targeting cannabinoid pathway→

Compare Skye Bioscience, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Skye Bioscience, Inc. operates in Biopharmaceuticals - Obesity and Metabolic Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Obesity and Metabolic Diseases research →
NEW · MCP server

Ask your AI assistant about Skye Bioscience, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Skye Bioscience, Inc. and its top competitor on Cyborg Score”
“What did Skye Bioscience, Inc. do this quarter?”
“Is Skye Bioscience, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Skye Bioscience, Inc. do?+
Skye Bioscience is a clinical stage biopharmaceutical company focused on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product ca...
What is Skye Bioscience, Inc.'s Cyborg Score?+
Skye Bioscience, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Skye Bioscience, Inc.'s main competitors?+
Named competitors include Semaglutide/Wegovy, Tirzepatide/Zepbound, Various CB1 Inhibitor Programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Skye Bioscience, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Skye Bioscience, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Skye Bioscience, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Obesity and Metabolic Diseases research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5Skye Bioscience, Inc.